Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Phase 2

Conditions: Recurrent Uterine Corpus Carcinoma
Endometrial Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7
Stage IV Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Metformin Hydrochloride
Drug: Paclitaxel
Other: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

Registration Number: NCT02065687

Lead Sponsor: Gynecologic Oncology Group

Brief Summary: This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin is more effective with or without metformin hydrochloride in treating endometrial cancer.

Detailed Description: PRIMARY OBJECTIVES:

I. To determine if the addition of metformin (metformin hydrochloride) to the standard regimen of carboplatin and paclitaxel prolongs progression-free survival (PFS) in women with advanced or recurrent endometrial cancer. (Phase II) II. To determine if the addition of metformin to the standard regimen of carboplatin and paclitaxel prolongs overall survival (OS) in the same population if a phase III study is conducted. Both clinical trials (Phase II and III) will utilize OS as a primary endpoint if a phase III trial is opened.

SECONDARY OBJECTIVES:

I. To estimate the proportion of patients with objective response (response rate \[RR\]) in the population of patients with measurable disease by treatment.

II. To estimate the duration of response in the population of patients with measurable disease who respond by treatment.

III. To estimate overall survival (OS) and relative hazards of death for each treatment arm if the study stops after the phase II trial is completed. If the study continues with a phase III clinical trial, then PFS will be a secondary endpoint.

IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm.

V. To estimate possible differences in RR, PFS, OS, and toxicity rates for the treatment regimens by the patients' level of obesity.

TERTIARY OBJECTIVES:

I. To test whether PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations have a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin.

II. To test whether higher expression of MATE 2 is associated with a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin.

III. To explore the association of metabolic factors (i.e. body mass index \[BMI\], hip-to-waist ratio, diabetes status, hemoglobin A1c \[HgbA1C\], fasting insulin and glucose levels, homeostatic model assessment \[HOMA\] scores) with treatment response to metformin/paclitaxel/carboplatin, PFS, and OS.

IV. To test whether genomic profiles (i.e. PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations) differ between the tumors of obese and non-obese endometrial cancer (EC) patients.

V. To correlate expression of key targets of the insulin/IGF-1/mTOR signaling pathway (p-IGF1R, p-S6 and p-4EBP-1) with treatment response to metformin/paclitaxel/carboplatin, PFS, OS and obesity status.

VI. To determine if the genetic variants of the metformin transporters correspond with treatment response to metformin/paclitaxel/carboplatin, PFS and OS.

VII. To estimate differences in physical functioning, physical activity, and fatigue between treatment arms.

VIII. To explore the association between metabolic factors (i.e., BMI, hip-to-waist ratio, diabetes status, HgbA1C, fasting insulin and glucose levels, HOMA scores) and physical functioning, physical activity, and fatigue.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride orally (PO) twice daily (BID) (approximately 10-12 hours apart) on days 1-21 (once daily \[QD\] in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

In both arms, patients who achieve stable disease (SD) or partial response (PR) and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Recruitment & Eligibility

Status: UNKNOWN

Sex: Female

Target Recruitment: 469

Inclusion Criteria

Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible:
  - Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
Platelets greater than or equal to 100,000/mcl
Creatinine less than 1.4 mg/dl
Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
Patients must be able to swallow and retain orally-administered medication
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study

Exclusion Criteria

Patients must NOT be taking metformin or have been on metformin in the past 6 months
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study
Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Laboratory Biomarker Analysis	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Paclitaxel	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Quality-of-Life Assessment	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Questionnaire Administration	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Laboratory Biomarker Analysis	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Paclitaxel	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Placebo Administration	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Quality-of-Life Assessment	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Questionnaire Administration	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Carboplatin	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm I (paclitaxel, carboplatin, metformin hydrochloride)	Metformin Hydrochloride	Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.
Arm II (paclitaxel, carboplatin, placebo)	Carboplatin	Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS) (Phase II and III)	From date of study entry to time of death or the date of last contact, assessed up to 5 years	The observed length of life from randomization into the study to death or the date of last contact. This study was originally designed as a phase II/III study. It passed the phase 2 threshold and started the phase 3; however, a phase 3 interim analysis stopped the trial for futility. Therefore, data available for Phase III may be identical to data reported for Phase II or Phase II/III combined.
Progression-free Survival (PFS) (Phase II)	From date of study entry to time of progression or death, whichever occurs first, assessed up to 5 years	Time until disease progression, death, or date of last contact. This study was originally designed as a phase II/III study. It passed the phase 2 threshold and started the phase 3; however, a phase 3 interim analysis stopped the trial for futility. Therefore, data available for Phase III may be identical to data reported for Phase II or Phase II/III combined.

Secondary Outcome Measures

Name	Time	Method
Proportion of Patients Responding to Therapy	During study treatment, up to 5 years.	The proportion of patients who had a response (complete or partial) by RECIST 1.1. Measurable disease is defined by RECIST (version 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or ≥ 20 mm when measured by chest x-ray. Lymph nodes must be \> 15 mm in short axis when measured by CT or MRI.
Duration of Response by Treatment	From the date of response to disease progression, death, or date last seen assessed up to 5 years	Duration of response until disease progression, death, or date last seen among patients who responded.
Overall Survival (OS) (Phase II)	From date of study entry to time of death or the date of last contact, assessed up to 5 years.	The observed length of life from randomization into the study to death or the date of last contact. For response, only those patients who had measurable disease were included in an analysis of response. Non-measurable patients are included in the ITT analysis. This study was originally designed as a phase II/III study. It passed the phase 2 threshold and started the phase 3; however, a phase 3 interim analysis stopped the trial for futility. Therefore, data available for Phase III may be identical to data reported for Phase II or Phase II/III combined.
Progression Free Survival (PFS) (Phase III)	From date of study entry to time of progression or death, whichever occurs first, assessed up to 5 years	Time until disease progression, death, or date of last contact. For response, only those patients who had measurable disease were included in an analysis of response. Non-measurable patients are included in the ITT analysis. This study was originally designed as a phase II/III study. It passed the phase 2 threshold and started the phase 3; however, a phase 3 interim analysis stopped the trial for futility. Therefore, data available for Phase III may be identical to data reported for Phase II or Phase II/III combined.
Number of Participants With Grade 3 or Higher Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4	Up to 5 years	Toxicities will be assessed by organ or organ system. For each category of toxicity, each patient will be evaluated by the worst grade experienced during the course of therapy. Data will be summarized by frequency and severity according to the regimen administered. The number of patients with a grade three or greater adverse event will be reported (by system organ class).
Level of Obesity	Up to 5 years	Obesity will be quantitative assessed by body mass index (BMI) and will be assessed for its predictive and prognostic significance. The interaction between BMI and metformin treatment will be examined with an interaction term in a Cox proportional hazards model.

Trial Locations

Locations (431): Novant Health Cancer Institute - Wilkesboro
🇺🇸
Wilkesboro, North Carolina, United States
Geisinger Medical Center
🇺🇸
Danville, Pennsylvania, United States
AnMed Health Cancer Center
🇺🇸
Anderson, South Carolina, United States
Kaiser Permanente Los Angeles Medical Center
🇺🇸
Los Angeles, California, United States
UT Southwestern/Simmons Cancer Center-Dallas
🇺🇸
Dallas, Texas, United States
Sinai Hospital of Baltimore
🇺🇸
Baltimore, Maryland, United States
Cedars Sinai Medical Center
🇺🇸
Los Angeles, California, United States
University of Mississippi Medical Center
🇺🇸
Jackson, Mississippi, United States
NYU Winthrop Hospital
🇺🇸
Mineola, New York, United States
Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
The Mark H Zangmeister Center
🇺🇸
Columbus, Ohio, United States
Columbus NCI Community Oncology Research Program
🇺🇸
Columbus, Ohio, United States
University of Pittsburgh Cancer Institute (UPCI)
🇺🇸
Pittsburgh, Pennsylvania, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
🇺🇸
Chicago, Illinois, United States
Case Western Reserve University
🇺🇸
Cleveland, Ohio, United States
Cleveland Clinic Cancer Center/Fairview Hospital
🇺🇸
Cleveland, Ohio, United States
Cleveland Clinic Foundation
🇺🇸
Cleveland, Ohio, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
🇺🇸
Baltimore, Maryland, United States
Fred Hutchinson Cancer Research Center
🇺🇸
Seattle, Washington, United States
University of Washington Medical Center - Northwest
🇺🇸
Seattle, Washington, United States
Women's Cancer Center of Seattle
🇺🇸
Seattle, Washington, United States
Seattle Cancer Care Alliance
🇺🇸
Seattle, Washington, United States
University of Washington Medical Center - Montlake
🇺🇸
Seattle, Washington, United States
Beth Israel Deaconess Medical Center
🇺🇸
Boston, Massachusetts, United States
Indiana University/Melvin and Bren Simon Cancer Center
🇺🇸
Indianapolis, Indiana, United States
Saint Vincent Hospital and Health Care Center
🇺🇸
Indianapolis, Indiana, United States
Lyndon Baines Johnson General Hospital
🇺🇸
Houston, Texas, United States
Houston Methodist Hospital
🇺🇸
Houston, Texas, United States
M D Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Memorial Hermann Texas Medical Center
🇺🇸
Houston, Texas, United States
Methodist Willowbrook Hospital
🇺🇸
Houston, Texas, United States
MD Anderson West Houston
🇺🇸
Houston, Texas, United States
University of Cincinnati Cancer Center-UC Medical Center
🇺🇸
Cincinnati, Ohio, United States
Bethesda North Hospital
🇺🇸
Cincinnati, Ohio, United States
Kaiser Permanente San Leandro
🇺🇸
San Leandro, California, United States
Abbott-Northwestern Hospital
🇺🇸
Minneapolis, Minnesota, United States
University of Minnesota/Masonic Cancer Center
🇺🇸
Minneapolis, Minnesota, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Zuckerberg San Francisco General Hospital
🇺🇸
San Francisco, California, United States
California Pacific Medical Center-Pacific Campus
🇺🇸
San Francisco, California, United States
Kaiser Permanente-San Francisco
🇺🇸
San Francisco, California, United States
UCSF Medical Center-Mount Zion
🇺🇸
San Francisco, California, United States
Huntsman Cancer Institute/University of Utah
🇺🇸
Salt Lake City, Utah, United States
LDS Hospital
🇺🇸
Salt Lake City, Utah, United States
Cancer Center at Saint Joseph's
🇺🇸
Phoenix, Arizona, United States
Saint Joseph's Hospital and Medical Center
🇺🇸
Phoenix, Arizona, United States
University of Oklahoma Health Sciences Center
🇺🇸
Oklahoma City, Oklahoma, United States
University of Alabama at Birmingham Cancer Center
🇺🇸
Birmingham, Alabama, United States
Mayo Clinic in Rochester
🇺🇸
Rochester, Minnesota, United States
Nebraska Methodist Hospital
🇺🇸
Omaha, Nebraska, United States
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
Minnesota Oncology Hematology PA-Woodbury
🇺🇸
Woodbury, Minnesota, United States
Mercy Clinic-Rolla-Cancer and Hematology
🇺🇸
Rolla, Missouri, United States
Saint Dominic-Jackson Memorial Hospital
🇺🇸
Jackson, Mississippi, United States
Cancer Research for the Ozarks NCORP
🇺🇸
Springfield, Missouri, United States
Center of Hope at Renown Medical Center
🇺🇸
Reno, Nevada, United States
Renown Regional Medical Center
🇺🇸
Reno, Nevada, United States
Cooper Hospital University Medical Center
🇺🇸
Camden, New Jersey, United States
Memorial Sloan Kettering Commack
🇺🇸
Commack, New York, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
🇺🇸
New York, New York, United States
Carolinas Medical Center/Levine Cancer Institute
🇺🇸
Charlotte, North Carolina, United States
Novant Health Cancer Institute - Statesville
🇺🇸
Statesville, North Carolina, United States
Novant Health Cancer Institute - Thomasville
🇺🇸
Thomasville, North Carolina, United States
Onslow Memorial Hospital
🇺🇸
Jacksonville, North Carolina, United States
New Hanover Regional Medical Center/Zimmer Cancer Center
🇺🇸
Wilmington, North Carolina, United States
Novant Health Cancer Institute - Kernersville
🇺🇸
Kernersville, North Carolina, United States
Sanford Roger Maris Cancer Center
🇺🇸
Fargo, North Dakota, United States
Sanford Clinic North-Fargo
🇺🇸
Fargo, North Dakota, United States
Summa Health System - Akron Campus
🇺🇸
Akron, Ohio, United States
Ohio State University Comprehensive Cancer Center
🇺🇸
Columbus, Ohio, United States
Good Samaritan Hospital - Dayton
🇺🇸
Dayton, Ohio, United States
ProMedica Flower Hospital
🇺🇸
Sylvania, Ohio, United States
Geisinger Medical Group
🇺🇸
State College, Pennsylvania, United States
Avera Cancer Institute
🇺🇸
Sioux Falls, South Dakota, United States
Gibbs Cancer Center-Pelham
🇺🇸
Greer, South Carolina, United States
Carolina Blood and Cancer Care Associates PA
🇺🇸
Rock Hill, South Carolina, United States
Sanford USD Medical Center - Sioux Falls
🇺🇸
Sioux Falls, South Dakota, United States
Texas Oncology-Austin Midtown
🇺🇸
Austin, Texas, United States
Texas Health Presbyterian Hospital Dallas
🇺🇸
Dallas, Texas, United States
MD Anderson in The Woodlands
🇺🇸
Conroe, Texas, United States
Texas Oncology Bedford
🇺🇸
Bedford, Texas, United States
Deke Slayton Cancer Center
🇺🇸
Webster, Texas, United States
Utah Cancer Specialists-Salt Lake City
🇺🇸
Salt Lake City, Utah, United States
Southwestern Vermont Medical Center
🇺🇸
Bennington, Vermont, United States
University of Virginia Cancer Center
🇺🇸
Charlottesville, Virginia, United States
University of Vermont and State Agricultural College
🇺🇸
Burlington, Vermont, United States
Edwards Comprehensive Cancer Center
🇺🇸
Huntington, West Virginia, United States
Monongalia Hospital
🇺🇸
Morgantown, West Virginia, United States
Saint Vincent Hospital Cancer Center Green Bay
🇺🇸
Green Bay, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Saint Mary's
🇺🇸
Green Bay, Wisconsin, United States
Marshfield Medical Center - Weston
🇺🇸
Weston, Wisconsin, United States
Arizona Oncology Associates-Wilmot
🇺🇸
Tucson, Arizona, United States
Arizona Oncology Associates-Biltmore Cancer Center
🇺🇸
Phoenix, Arizona, United States
Arizona Oncology Associates-West Orange Grove
🇺🇸
Tucson, Arizona, United States
Palo Alto Medical Foundation-Santa Cruz
🇺🇸
Santa Cruz, California, United States
Palo Alto Medical Foundation-Gynecologic Oncology
🇺🇸
Mountain View, California, United States
Kaiser Permanente-South San Francisco
🇺🇸
South San Francisco, California, United States
Smilow Cancer Hospital Care Center - Guiford
🇺🇸
Guilford, Connecticut, United States
Hartford Hospital
🇺🇸
Hartford, Connecticut, United States
Smilow Cancer Hospital Care Center at Saint Francis
🇺🇸
Hartford, Connecticut, United States
Smilow Cancer Hospital Care Center-Fairfield
🇺🇸
Fairfield, Connecticut, United States
Pali Momi Medical Center
🇺🇸
'Aiea, Hawaii, United States
Women's Cancer Associates
🇺🇸
Saint Petersburg, Florida, United States
Emory University Hospital Midtown
🇺🇸
Atlanta, Georgia, United States
Beebe Health Campus
🇺🇸
Rehoboth Beach, Delaware, United States
Illinois CancerCare-Bloomington
🇺🇸
Bloomington, Illinois, United States
Carle on Vermilion
🇺🇸
Danville, Illinois, United States
Carle Physician Group-Effingham
🇺🇸
Effingham, Illinois, United States
Illinois CancerCare-Peru
🇺🇸
Peru, Illinois, United States
Illinois CancerCare-Pekin
🇺🇸
Pekin, Illinois, United States
Sudarshan K Sharma MD Limited-Gynecologic Oncology
🇺🇸
Hinsdale, Illinois, United States
North Shore Medical Center
🇺🇸
Skokie, Illinois, United States
Illinois CancerCare-Peoria
🇺🇸
Peoria, Illinois, United States
Michiana Hematology Oncology PC-Crown Point
🇺🇸
Crown Point, Indiana, United States
Carle Cancer Center
🇺🇸
Urbana, Illinois, United States
Michiana Hematology Oncology PC-Elkhart
🇺🇸
Elkhart, Indiana, United States
Michiana Hematology Oncology PC-Westville
🇺🇸
Westville, Indiana, United States
Woodland Cancer Care Center
🇺🇸
Michigan City, Indiana, United States
Michiana Hematology Oncology PC-South Bend
🇺🇸
South Bend, Indiana, United States
Saint Joseph Mercy Oakland
🇺🇸
Pontiac, Michigan, United States
Saint John Macomb-Oakland Hospital
🇺🇸
Warren, Michigan, United States
Spectrum Health Reed City Hospital
🇺🇸
Reed City, Michigan, United States
Delbert Day Cancer Institute at PCRMC
🇺🇸
Rolla, Missouri, United States
Barnes-Jewish Hospital
🇺🇸
Saint Louis, Missouri, United States
Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
🇺🇸
Tulsa, Oklahoma, United States
Southeastern Medical Oncology Center-Goldsboro
🇺🇸
Goldsboro, North Carolina, United States
AdventHealth Hendersonville
🇺🇸
Hendersonville, North Carolina, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
University of Arizona Cancer Center-North Campus
🇺🇸
Tucson, Arizona, United States
Adams Cancer Center
🇺🇸
Gettysburg, Pennsylvania, United States
UPMC Uniontown Hospital Radiation Oncology
🇺🇸
Uniontown, Pennsylvania, United States
Illinois CancerCare-Macomb
🇺🇸
Macomb, Illinois, United States
Central Illinois Hematology Oncology Center
🇺🇸
Springfield, Illinois, United States
University of Colorado Hospital
🇺🇸
Aurora, Colorado, United States
Walter Reed National Military Medical Center
🇺🇸
Bethesda, Maryland, United States
Novant Health Presbyterian Medical Center
🇺🇸
Charlotte, North Carolina, United States
Mercy Hospital Saint Louis
🇺🇸
Saint Louis, Missouri, United States
Tennessee Valley Gynecologic Oncology
🇺🇸
Huntsville, Alabama, United States
Banner University Medical Center - Tucson
🇺🇸
Tucson, Arizona, United States
John Muir Medical Center-Concord Campus
🇺🇸
Concord, California, United States
University of Arkansas for Medical Sciences
🇺🇸
Little Rock, Arkansas, United States
Los Angeles County-USC Medical Center
🇺🇸
Los Angeles, California, United States
UC San Diego Moores Cancer Center
🇺🇸
La Jolla, California, United States
Kaiser Permanente-Oakland
🇺🇸
Oakland, California, United States
UCLA / Jonsson Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
Palo Alto Medical Foundation Health Care
🇺🇸
Palo Alto, California, United States
Saint Joseph Hospital - Orange
🇺🇸
Orange, California, United States
Stanford Cancer Institute Palo Alto
🇺🇸
Palo Alto, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
🇺🇸
Orange, California, United States
Keck Medical Center of USC Pasadena
🇺🇸
Pasadena, California, United States
Kaiser Permanente-Roseville
🇺🇸
Roseville, California, United States
UCSF Medical Center-Mission Bay
🇺🇸
San Francisco, California, United States
Kaiser Permanente-Santa Teresa-San Jose
🇺🇸
San Jose, California, United States
Kaiser Permanente Medical Center - Santa Clara
🇺🇸
Santa Clara, California, United States
Kaiser Permanente-Vallejo
🇺🇸
Vallejo, California, United States
Olive View-University of California Los Angeles Medical Center
🇺🇸
Sylmar, California, United States
Palo Alto Medical Foundation-Sunnyvale
🇺🇸
Sunnyvale, California, United States
John Muir Medical Center-Walnut Creek
🇺🇸
Walnut Creek, California, United States
Kaiser Permanente-Walnut Creek
🇺🇸
Walnut Creek, California, United States
Smilow Cancer Hospital-Derby Care Center
🇺🇸
Derby, Connecticut, United States
Poudre Valley Hospital
🇺🇸
Fort Collins, Colorado, United States
Penrose-Saint Francis Healthcare
🇺🇸
Colorado Springs, Colorado, United States
Midstate Medical Center
🇺🇸
Meriden, Connecticut, United States
The Hospital of Central Connecticut
🇺🇸
New Britain, Connecticut, United States
Yale-New Haven Hospital North Haven Medical Center
🇺🇸
North Haven, Connecticut, United States
Smilow Cancer Hospital-Orange Care Center
🇺🇸
Orange, Connecticut, United States
Smilow Cancer Hospital Care Center-Trumbull
🇺🇸
Trumbull, Connecticut, United States
Smilow Cancer Hospital-Torrington Care Center
🇺🇸
Torrington, Connecticut, United States
Smilow Cancer Hospital-Waterbury Care Center
🇺🇸
Waterbury, Connecticut, United States
Christiana Gynecologic Oncology LLC
🇺🇸
Newark, Delaware, United States
Christiana Care Health System-Christiana Hospital
🇺🇸
Newark, Delaware, United States
Christiana Care Health System-Wilmington Hospital
🇺🇸
Wilmington, Delaware, United States
Medical Oncology Hematology Consultants PA
🇺🇸
Newark, Delaware, United States
Helen F Graham Cancer Center
🇺🇸
Newark, Delaware, United States
Sarasota Memorial Hospital
🇺🇸
Sarasota, Florida, United States
Northside Hospital
🇺🇸
Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
Augusta University Medical Center
🇺🇸
Augusta, Georgia, United States
Dekalb Medical Center
🇺🇸
Decatur, Georgia, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
🇺🇸
Savannah, Georgia, United States
Northeast Georgia Medical Center-Gainesville
🇺🇸
Gainesville, Georgia, United States
Queen's Cancer Center - Pearlridge
🇺🇸
'Aiea, Hawaii, United States
The Cancer Center of Hawaii-Pali Momi
🇺🇸
'Aiea, Hawaii, United States
Rush - Copley Medical Center
🇺🇸
Aurora, Illinois, United States
Wilcox Memorial Hospital and Kauai Medical Clinic
🇺🇸
Lihue, Hawaii, United States
Northwest Community Hospital
🇺🇸
Arlington Heights, Illinois, United States
Saint Alphonsus Cancer Care Center-Boise
🇺🇸
Boise, Idaho, United States
Illinois CancerCare-Carthage
🇺🇸
Carthage, Illinois, United States
Cancer Care Specialists of Illinois - Decatur
🇺🇸
Decatur, Illinois, United States
Illinois CancerCare-Canton
🇺🇸
Canton, Illinois, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Decatur Memorial Hospital
🇺🇸
Decatur, Illinois, United States
Crossroads Cancer Center
🇺🇸
Effingham, Illinois, United States
Illinois CancerCare-Eureka
🇺🇸
Eureka, Illinois, United States
Northwestern Medicine Cancer Center Delnor
🇺🇸
Geneva, Illinois, United States
NorthShore University HealthSystem-Evanston Hospital
🇺🇸
Evanston, Illinois, United States
AMITA Health Alexian Brothers Medical Center
🇺🇸
Elk Grove Village, Illinois, United States
NorthShore University HealthSystem-Highland Park Hospital
🇺🇸
Highland Park, Illinois, United States
Illinois CancerCare-Galesburg
🇺🇸
Galesburg, Illinois, United States
NorthShore University HealthSystem-Glenbrook Hospital
🇺🇸
Glenview, Illinois, United States
Illinois CancerCare-Kewanee Clinic
🇺🇸
Kewanee, Illinois, United States
UC Comprehensive Cancer Center at Silver Cross
🇺🇸
New Lenox, Illinois, United States
Carle Physician Group-Mattoon/Charleston
🇺🇸
Mattoon, Illinois, United States
Cancer Care Center of O'Fallon
🇺🇸
O'Fallon, Illinois, United States
Illinois CancerCare-Ottawa Clinic
🇺🇸
Ottawa, Illinois, United States
University of Chicago Medicine-Orland Park
🇺🇸
Orland Park, Illinois, United States
Illinois CancerCare-Princeton
🇺🇸
Princeton, Illinois, United States
Springfield Clinic
🇺🇸
Springfield, Illinois, United States
Southern Illinois University School of Medicine
🇺🇸
Springfield, Illinois, United States
Memorial Medical Center
🇺🇸
Springfield, Illinois, United States
Northwestern Medicine Cancer Center Warrenville
🇺🇸
Warrenville, Illinois, United States
Rush-Copley Healthcare Center
🇺🇸
Yorkville, Illinois, United States
The Carle Foundation Hospital
🇺🇸
Urbana, Illinois, United States
Elkhart General Hospital
🇺🇸
Elkhart, Indiana, United States
IU Health La Porte Hospital
🇺🇸
La Porte, Indiana, United States
Michiana Hematology Oncology PC-Mishawaka
🇺🇸
Mishawaka, Indiana, United States
Franciscan Saint Anthony Health-Michigan City
🇺🇸
Michigan City, Indiana, United States
Saint Joseph Regional Medical Center-Mishawaka
🇺🇸
Mishawaka, Indiana, United States
Mary Greeley Medical Center
🇺🇸
Ames, Iowa, United States
McFarland Clinic PC-Boone
🇺🇸
Boone, Iowa, United States
Medical Oncology and Hematology Associates-West Des Moines
🇺🇸
Clive, Iowa, United States
Mercy Cancer Center-West Lakes
🇺🇸
Clive, Iowa, United States
McFarland Clinic PC-Trinity Cancer Center
🇺🇸
Fort Dodge, Iowa, United States
University of Iowa/Holden Comprehensive Cancer Center
🇺🇸
Iowa City, Iowa, United States
McFarland Clinic PC-Jefferson
🇺🇸
Jefferson, Iowa, United States
McFarland Clinic PC-Marshalltown
🇺🇸
Marshalltown, Iowa, United States
Saint Elizabeth Medical Center South
🇺🇸
Edgewood, Kentucky, United States
Mercy Medical Center - North Iowa
🇺🇸
Mason City, Iowa, United States
Saint Elizabeth Fort Thomas
🇺🇸
Fort Thomas, Kentucky, United States
Woman's Hospital
🇺🇸
Baton Rouge, Louisiana, United States
McFarland Clinic PC - Ames
🇺🇸
Ames, Iowa, United States
Greater Baltimore Medical Center
🇺🇸
Baltimore, Maryland, United States
Maine Medical Center- Scarborough Campus
🇺🇸
Scarborough, Maine, United States
Brigham and Women's Hospital
🇺🇸
Boston, Massachusetts, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Lowell General Hospital
🇺🇸
Lowell, Massachusetts, United States
Baystate Medical Center
🇺🇸
Springfield, Massachusetts, United States
UMass Memorial Medical Center - Memorial Division
🇺🇸
Worcester, Massachusetts, United States
Bronson Battle Creek
🇺🇸
Battle Creek, Michigan, United States
Green Bay Oncology - Escanaba
🇺🇸
Escanaba, Michigan, United States
Beaumont Hospital - Dearborn
🇺🇸
Dearborn, Michigan, United States
Wayne State University/Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Weisberg Cancer Treatment Center
🇺🇸
Farmington Hills, Michigan, United States
Hurley Medical Center
🇺🇸
Flint, Michigan, United States
Genesys Hurley Cancer Institute
🇺🇸
Flint, Michigan, United States
Mercy Health Saint Mary's
🇺🇸
Grand Rapids, Michigan, United States
Helen DeVos Children's Hospital at Spectrum Health
🇺🇸
Grand Rapids, Michigan, United States
Spectrum Health at Butterworth Campus
🇺🇸
Grand Rapids, Michigan, United States
Sparrow Hospital
🇺🇸
Lansing, Michigan, United States
Green Bay Oncology - Iron Mountain
🇺🇸
Iron Mountain, Michigan, United States
Allegiance Health
🇺🇸
Jackson, Michigan, United States
Monroe Cancer Center
🇺🇸
Monroe, Michigan, United States
Mercy Health Mercy Campus
🇺🇸
Muskegon, Michigan, United States
West Michigan Cancer Center
🇺🇸
Kalamazoo, Michigan, United States
Saint Mary Mercy Hospital
🇺🇸
Livonia, Michigan, United States
Lake Huron Medical Center
🇺🇸
Port Huron, Michigan, United States
William Beaumont Hospital-Royal Oak
🇺🇸
Royal Oak, Michigan, United States
Munson Medical Center
🇺🇸
Traverse City, Michigan, United States
Ascension Saint Mary's Hospital
🇺🇸
Saginaw, Michigan, United States
William Beaumont Hospital - Troy
🇺🇸
Troy, Michigan, United States
Sanford Joe Lueken Cancer Center
🇺🇸
Bemidji, Minnesota, United States
Mercy Hospital
🇺🇸
Coon Rapids, Minnesota, United States
Fairview Southdale Hospital
🇺🇸
Edina, Minnesota, United States
Metro Minnesota Community Oncology Research Consortium
🇺🇸
Saint Louis Park, Minnesota, United States
United Hospital
🇺🇸
Saint Paul, Minnesota, United States
Park Nicollet Clinic - Saint Louis Park
🇺🇸
Saint Louis Park, Minnesota, United States
Lakeview Hospital
🇺🇸
Stillwater, Minnesota, United States
Saint Francis Medical Center
🇺🇸
Cape Girardeau, Missouri, United States
Mercy Hospital Springfield
🇺🇸
Springfield, Missouri, United States
CoxHealth South Hospital
🇺🇸
Springfield, Missouri, United States
CHI Health Saint Francis
🇺🇸
Grand Island, Nebraska, United States
Benefis Healthcare- Sletten Cancer Institute
🇺🇸
Great Falls, Montana, United States
Kalispell Regional Medical Center
🇺🇸
Kalispell, Montana, United States
CHI Health Good Samaritan
🇺🇸
Kearney, Nebraska, United States
University of Nebraska Medical Center
🇺🇸
Omaha, Nebraska, United States
Women's Cancer Center of Nevada
🇺🇸
Las Vegas, Nevada, United States
Wentworth-Douglass Hospital
🇺🇸
Dover, New Hampshire, United States
Dartmouth Hitchcock Medical Center
🇺🇸
Lebanon, New Hampshire, United States
Memorial Sloan Kettering Monmouth
🇺🇸
Middletown, New Jersey, United States
Memorial Sloan Kettering Basking Ridge
🇺🇸
Basking Ridge, New Jersey, United States
Virtua Memorial
🇺🇸
Mount Holly, New Jersey, United States
Virtua Voorhees
🇺🇸
Voorhees, New Jersey, United States
Morristown Medical Center
🇺🇸
Morristown, New Jersey, United States
MD Anderson Cancer Center at Cooper-Voorhees
🇺🇸
Voorhees, New Jersey, United States
Overlook Hospital
🇺🇸
Summit, New Jersey, United States
Women's Cancer Care Associates LLC
🇺🇸
Albany, New York, United States
Glens Falls Hospital
🇺🇸
Glens Falls, New York, United States
New York-Presbyterian/Brooklyn Methodist Hospital
🇺🇸
Brooklyn, New York, United States
State University of New York Downstate Medical Center
🇺🇸
Brooklyn, New York, United States
Roswell Park Cancer Institute
🇺🇸
Buffalo, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Westchester
🇺🇸
Harrison, New York, United States
Memorial Sloan Kettering Sleepy Hollow
🇺🇸
Sleepy Hollow, New York, United States
Mount Sinai Union Square
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸
New York, New York, United States
Mount Sinai Hospital
🇺🇸
New York, New York, United States
Memorial Sloan Kettering Nassau
🇺🇸
Uniondale, New York, United States
Stony Brook University Medical Center
🇺🇸
Stony Brook, New York, United States
Westchester Medical Center
🇺🇸
Valhalla, New York, United States
Dickstein Cancer Treatment Center
🇺🇸
White Plains, New York, United States
Atrium Health Cabarrus/LCI-Concord
🇺🇸
Concord, North Carolina, United States
Southeastern Medical Oncology Center-Clinton
🇺🇸
Clinton, North Carolina, United States
Wayne Memorial Hospital
🇺🇸
Goldsboro, North Carolina, United States
Southeastern Medical Oncology Center-Jacksonville
🇺🇸
Jacksonville, North Carolina, United States
Novant Health Cancer Institute - Mount Airy
🇺🇸
Mount Airy, North Carolina, United States
FirstHealth of the Carolinas-Moore Regional Hospital
🇺🇸
Pinehurst, North Carolina, United States
Duke Raleigh Hospital
🇺🇸
Raleigh, North Carolina, United States
Sanford Bismarck Medical Center
🇺🇸
Bismarck, North Dakota, United States
Sanford Broadway Medical Center
🇺🇸
Fargo, North Dakota, United States
Good Samaritan Hospital - Cincinnati
🇺🇸
Cincinnati, Ohio, United States
Riverside Methodist Hospital
🇺🇸
Columbus, Ohio, United States
Grandview Hospital
🇺🇸
Dayton, Ohio, United States
Miami Valley Hospital
🇺🇸
Dayton, Ohio, United States
Hillcrest Hospital Cancer Center
🇺🇸
Mayfield Heights, Ohio, United States
UH Seidman Cancer Center at Lake Health Mentor Campus
🇺🇸
Mentor, Ohio, United States
Miami Valley Hospital North
🇺🇸
Dayton, Ohio, United States
Wright-Patterson Medical Center
🇺🇸
Wright-Patterson Air Force Base, Ohio, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
🇺🇸
Toledo, Ohio, United States
Jefferson Abington Hospital
🇺🇸
Abington, Pennsylvania, United States
Saint Luke's University Hospital-Bethlehem Campus
🇺🇸
Bethlehem, Pennsylvania, United States
UPMC Cancer Centers - Arnold Palmer Pavilion
🇺🇸
Greensburg, Pennsylvania, United States
Geisinger Medical Center-Cancer Center Hazleton
🇺🇸
Hazleton, Pennsylvania, United States
Cherry Tree Cancer Center
🇺🇸
Hanover, Pennsylvania, United States
University of Pennsylvania/Abramson Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Geisinger Medical Oncology-Lewisburg
🇺🇸
Lewisburg, Pennsylvania, United States
Lewistown Hospital
🇺🇸
Lewistown, Pennsylvania, United States
Temple University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Geisinger Cancer Services-Pottsville
🇺🇸
Pottsville, Pennsylvania, United States
UPMC-Magee Womens Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC-Passavant Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
UPMC Cancer Center at UPMC Northwest
🇺🇸
Seneca, Pennsylvania, United States
Chester County Hospital
🇺🇸
West Chester, Pennsylvania, United States
WellSpan Health-York Hospital
🇺🇸
York, Pennsylvania, United States
Reading Hospital
🇺🇸
West Reading, Pennsylvania, United States
Geisinger Wyoming Valley/Henry Cancer Center
🇺🇸
Wilkes-Barre, Pennsylvania, United States
Women and Infants Hospital
🇺🇸
Providence, Rhode Island, United States
Saint Francis Hospital
🇺🇸
Greenville, South Carolina, United States
Black Hills Obstetrics and Gynecology
🇺🇸
Rapid City, South Dakota, United States
Carolina Blood and Cancer Care Associates PA-Lancaster
🇺🇸
Lancaster, South Carolina, United States
Spartanburg Medical Center
🇺🇸
Spartanburg, South Carolina, United States
Rapid City Regional Hospital
🇺🇸
Rapid City, South Dakota, United States
Sanford Cancer Center Oncology Clinic
🇺🇸
Sioux Falls, South Dakota, United States
Chattanooga's Program in Women's Oncology
🇺🇸
Chattanooga, Tennessee, United States
University of Tennessee - Knoxville
🇺🇸
Knoxville, Tennessee, United States
Parkland Memorial Hospital
🇺🇸
Dallas, Texas, United States
Texas Oncology at Baylor Charles A Sammons Cancer Center
🇺🇸
Dallas, Texas, United States
Texas Oncology - Fort Worth Cancer Center
🇺🇸
Fort Worth, Texas, United States
MD Anderson League City
🇺🇸
League City, Texas, United States
MD Anderson in Sugar Land
🇺🇸
Sugar Land, Texas, United States
Houston Methodist Sugar Land Hospital
🇺🇸
Sugar Land, Texas, United States
Texas Oncology-The Woodlands
🇺🇸
The Woodlands, Texas, United States
Texas Oncology Cancer Center Sugar Land
🇺🇸
Sugar Land, Texas, United States
Tyler Cancer Center
🇺🇸
Tyler, Texas, United States
American Fork Hospital / Huntsman Intermountain Cancer Center
🇺🇸
American Fork, Utah, United States
Logan Regional Hospital
🇺🇸
Logan, Utah, United States
Sandra L Maxwell Cancer Center
🇺🇸
Cedar City, Utah, United States
Intermountain Medical Center
🇺🇸
Murray, Utah, United States
McKay-Dee Hospital Center
🇺🇸
Ogden, Utah, United States
Utah Valley Regional Medical Center
🇺🇸
Provo, Utah, United States
Dixie Medical Center Regional Cancer Center
🇺🇸
Saint George, Utah, United States
Central Vermont Medical Center/National Life Cancer Treatment
🇺🇸
Berlin, Vermont, United States
University of Vermont Medical Center
🇺🇸
Burlington, Vermont, United States
Norris Cotton Cancer Center-North
🇺🇸
Saint Johnsbury, Vermont, United States
Inova Schar Cancer Institute
🇺🇸
Fairfax, Virginia, United States
Inova Fairfax Hospital
🇺🇸
Falls Church, Virginia, United States
Highline Medical Center-Main Campus
🇺🇸
Burien, Washington, United States
Carilion Clinic Gynecological Oncology
🇺🇸
Roanoke, Virginia, United States
MultiCare Gig Harbor Medical Park
🇺🇸
Gig Harbor, Washington, United States
MultiCare Tacoma General Hospital
🇺🇸
Tacoma, Washington, United States
Marshfield Clinic Cancer Center at Sacred Heart
🇺🇸
Eau Claire, Wisconsin, United States
Marshfield Clinic-Chippewa Center
🇺🇸
Chippewa Falls, Wisconsin, United States
Green Bay Oncology at Saint Vincent Hospital
🇺🇸
Green Bay, Wisconsin, United States
Green Bay Oncology Limited at Saint Mary's Hospital
🇺🇸
Green Bay, Wisconsin, United States
Holy Family Memorial Hospital
🇺🇸
Manitowoc, Wisconsin, United States
Marshfield Medical Center-Marshfield
🇺🇸
Marshfield, Wisconsin, United States
ProHealth Oconomowoc Memorial Hospital
🇺🇸
Oconomowoc, Wisconsin, United States
Marshfield Medical Center-Rice Lake
🇺🇸
Rice Lake, Wisconsin, United States
ProHealth D N Greenwald Center
🇺🇸
Mukwonago, Wisconsin, United States
Marshfield Clinic Stevens Point Center
🇺🇸
Stevens Point, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Oconto Falls
🇺🇸
Oconto Falls, Wisconsin, United States
Green Bay Oncology - Sturgeon Bay
🇺🇸
Sturgeon Bay, Wisconsin, United States
ProHealth Waukesha Memorial Hospital
🇺🇸
Waukesha, Wisconsin, United States
Saint Vincent Hospital Cancer Center at Sturgeon Bay
🇺🇸
Sturgeon Bay, Wisconsin, United States
Aspirus Regional Cancer Center
🇺🇸
Wausau, Wisconsin, United States
UW Cancer Center at ProHealth Care
🇺🇸
Waukesha, Wisconsin, United States
Marshfield Clinic-Wausau Center
🇺🇸
Wausau, Wisconsin, United States
Marshfield Clinic - Wisconsin Rapids Center
🇺🇸
Wisconsin Rapids, Wisconsin, United States
Wake Forest University Health Sciences
🇺🇸
Winston-Salem, North Carolina, United States
Novant Health Oncology Specialists
🇺🇸
Winston-Salem, North Carolina, United States
Winston-Salem Health Care
🇺🇸
Winston-Salem, North Carolina, United States
University of California Davis Comprehensive Cancer Center
🇺🇸
Sacramento, California, United States
Kaiser Permanente - Sacramento
🇺🇸
Sacramento, California, United States
Michigan Cancer Research Consortium NCORP
🇺🇸
Ann Arbor, Michigan, United States
University of Michigan Comprehensive Cancer Center
🇺🇸
Ann Arbor, Michigan, United States
Saint Joseph Mercy Hospital
🇺🇸
Ann Arbor, Michigan, United States
University of Hawaii Cancer Center
🇺🇸
Honolulu, Hawaii, United States
The Cancer Center of Hawaii-Liliha
🇺🇸
Honolulu, Hawaii, United States
Yale University
🇺🇸
New Haven, Connecticut, United States
AdventHealth Orlando
🇺🇸
Orlando, Florida, United States
UNC Lineberger Comprehensive Cancer Center
🇺🇸
Chapel Hill, North Carolina, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
University of Florida Health Science Center - Gainesville
🇺🇸
Gainesville, Florida, United States
Straub Clinic and Hospital
🇺🇸
Honolulu, Hawaii, United States
Ochsner Medical Center Jefferson
🇺🇸
New Orleans, Louisiana, United States
Hawaii Cancer Care Inc-Liliha
🇺🇸
Honolulu, Hawaii, United States
Dell Seton Medical Center at The University of Texas
🇺🇸
Austin, Texas, United States
Texas Oncology - Central Austin Cancer Center
🇺🇸
Austin, Texas, United States
Texas Oncology - South Austin Cancer Center
🇺🇸
Austin, Texas, United States
Virginia Commonwealth University/Massey Cancer Center
🇺🇸
Richmond, Virginia, United States
Henrico Doctor's Hospital
🇺🇸
Richmond, Virginia, United States
Virginia Gynecologic Oncology
🇺🇸
Richmond, Virginia, United States
Hawaii Cancer Care Inc - Waterfront Plaza
🇺🇸
Honolulu, Hawaii, United States
Queen's Medical Center
🇺🇸
Honolulu, Hawaii, United States
Kapiolani Medical Center for Women and Children
🇺🇸
Honolulu, Hawaii, United States
Kuakini Medical Center
🇺🇸
Honolulu, Hawaii, United States
Queen's Cancer Center - Kuakini
🇺🇸
Honolulu, Hawaii, United States
Montefiore Medical Center-Einstein Campus
🇺🇸
Bronx, New York, United States
Montefiore Medical Center-Weiler Hospital
🇺🇸
Bronx, New York, United States
Montefiore Medical Center - Moses Campus
🇺🇸
Bronx, New York, United States
Medical Oncology and Hematology Associates-Laurel
🇺🇸
Des Moines, Iowa, United States
Mercy Medical Center - Des Moines
🇺🇸
Des Moines, Iowa, United States
University of Kentucky/Markey Cancer Center
🇺🇸
Lexington, Kentucky, United States
University of New Mexico Cancer Center
🇺🇸
Albuquerque, New Mexico, United States
Southwest Gynecologic Oncology Associates Inc
🇺🇸
Albuquerque, New Mexico, United States
University of Wisconsin Hospital and Clinics
🇺🇸
Madison, Wisconsin, United States
Billings Clinic Cancer Center
🇺🇸
Billings, Montana, United States
Texas Oncology-Longview Cancer Center
🇺🇸
Longview, Texas, United States

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts